PIM447 (LGH447) is primarily used in the field of oncology as a potential therapeutic agent. It functions as a potent and selective inhibitor of PIM kinases, which are enzymes that play a critical role in cell survival, proliferation, and apoptosis. By targeting these kinases, PIM447 has shown promise in preclinical studies for treating various cancers, particularly hematologic malignancies such as multiple myeloma and acute myeloid leukemia (AML). Its ability to disrupt signaling pathways that promote tumor growth and resistance to apoptosis makes it a candidate for combination therapies with other anticancer drugs. Additionally, research is ongoing to explore its efficacy in solid tumors and its potential to overcome drug resistance in cancer treatment.